A game changer for Americans who can't afford these drugs otherwise
In the waning weeks of his administration, President Biden has proposed extending Medicare and Medicaid coverage to a new class of weight-loss drugs, reframing obesity not as a personal failing but as a treatable disease deserving federal care. The move would open access to medications like Wegovy and Ozempic for millions of Americans who have watched these drugs transform lives they could not afford to change. Yet the proposal lands in the shadow of a political transition, where a new administration and a skeptical HHS nominee may yet decide that the nation's weight problem deserves a different kind of answer.
- Millions of low-income and elderly Americans have been priced out of weight-loss drugs costing over $1,000 a month — this proposal would change that overnight for up to 7.5 million people.
- The Biden administration is racing against its own expiration date, pushing a rule that won't be finalized until January, days after power changes hands.
- RFK Jr., Trump's pick to lead HHS, has publicly rejected the pharmaceutical approach, calling instead for organic food subsidies and gym memberships as a cheaper, more holistic fix.
- A $35 billion price tag over ten years makes this proposal a lightning rod for Republicans already sharpening their knives for government spending cuts.
- The pharmaceutical industry, which lobbied hard for this expansion, now faces its biggest obstacle not in Congress but in the incoming Cabinet.
On a Tuesday morning in late November, the Biden administration proposed a rule that would allow Medicare and Medicaid to cover expensive weight-loss drugs like Wegovy and Ozempic — medications that have reshaped conversations about obesity but remained financially out of reach for most Americans. The Department of Health and Human Services estimates 3.5 million Medicare beneficiaries and 4 million Medicaid recipients could qualify, though internal data suggests the true eligible population could be far larger.
The drugs, manufactured by Novo Nordisk and Eli Lilly, mimic appetite-regulating hormones and can help patients lose 15 to 25 percent of their body weight. A month's supply of Wegovy runs $1,300. For most Americans without robust insurance, that cost has been the end of the conversation. HHS Secretary Xavier Becerra called the proposal a matter of equity: "It's a game changer for Americans who can't afford these drugs otherwise."
The administration also argues the investment could pay for itself by preventing costlier downstream treatments — diabetes care, cardiac interventions, stroke recovery — that already burden public insurance programs. A bipartisan group of lawmakers has made similar arguments on Capitol Hill.
But the proposal's survival is far from certain. The rule won't be finalized until January, days after Donald Trump is inaugurated. Robert F. Kennedy Jr., Trump's nominee to lead HHS, has argued forcefully against pharmaceutical solutions to obesity, suggesting the same money could instead fund organic food and gym memberships for every obese American. As a future Cabinet secretary, Kennedy would have significant power to block or rewrite the rule.
The proposal also carries a deeper legal significance. For decades, federal statute has barred Medicare from covering weight-loss products. By classifying obesity as a treatable disease rather than a lifestyle condition, the Biden administration is attempting to rewrite that framework — a philosophical shift whose staying power now depends entirely on who holds power in Washington come January.
On a Tuesday morning in late November, the Biden administration unveiled a proposal that would fundamentally reshape how the federal government pays for weight-loss drugs. Under the new rule from the Department of Health and Human Services, millions of Americans struggling with obesity would become eligible for Medicare or Medicaid coverage of expensive injectables like Wegovy and Ozempic—medications that have captured public imagination and celebrity endorsement in equal measure.
The scale of the potential impact is substantial. The administration estimates that 3.5 million additional Medicare beneficiaries and 4 million Medicaid recipients could qualify for coverage, though internal government data suggests the actual number could be far larger—roughly 28 million Medicaid enrollees alone meet the clinical definition of obesity. To qualify, patients would need a body mass index of 30 or higher. Some people already receive coverage through these programs if they have diabetes or cardiovascular risk factors, but this proposal would expand access based on obesity alone.
The drugs themselves represent a significant medical development. Manufactured by companies like Novo Nordisk and Eli Lilly, these weekly injectables work by mimicking hormones that regulate appetite, essentially signaling fullness to the brain during eating. Clinical data shows patients can lose between 15 and 25 percent of their body weight. Until now, cost has been the primary barrier to access. A month's supply of Wegovy costs $1,300; Zepbound runs $1,000. For most Americans without insurance coverage or substantial wealth, these medications have remained out of reach.
Health and Human Services Secretary Xavier Becerra framed the proposal as a matter of equity and public health. "It's a good day for anyone who suffers from obesity," he said. "It's a game changer for Americans who can't afford these drugs otherwise." The administration also points to potential long-term savings. A bipartisan group of lawmakers has argued that covering these drugs could prevent far costlier treatments for obesity-related conditions—diabetes management, cardiac care, stroke recovery—that currently drain government and private insurance resources.
But the proposal arrives at a moment of profound political uncertainty. The rule will not be finalized until January, days after Donald Trump takes office as president. This timing creates a critical vulnerability. Robert F. Kennedy Jr., Trump's nominee to lead the HHS, has been a vocal opponent of the weight-loss drug expansion. Kennedy has argued instead for a fundamentally different approach: using the same resources to subsidize organic food and gym memberships for obese Americans. "For half the price of Ozempic, we could purchase regeneratively raised, organic food for every American, three meals a day and a gym membership, for every obese American," he said during a roundtable with federal lawmakers earlier this year.
The financial stakes are substantial. The proposal could cost taxpayers as much as $35 billion over the next decade. For an incoming administration and Cabinet picks committed to reducing government spending, that price tag presents an immediate political problem. Kennedy, who must be confirmed by the Senate before assuming the HHS role, has the power to block or substantially alter the rule once he takes office. The pharmaceutical industry, which has lobbied heavily for Medicare and Medicaid coverage, now faces a showdown with one of the most influential voices in Trump's circle.
The proposal also represents a legal and philosophical shift. For decades, a federal statute has prohibited Medicare from covering weight-loss products. The Biden administration's rule reframes obesity itself as a treatable disease rather than a lifestyle issue, which would allow the government insurance program to cover pharmaceutical interventions. Whether that framing survives the transition to a new administration remains an open question.
Notable Quotes
It's a good day for anyone who suffers from obesity. It's a game changer for Americans who can't afford these drugs otherwise.— Xavier Becerra, HHS Secretary
For half the price of Ozempic, we could purchase regeneratively raised, organic food for every American, three meals a day and a gym membership, for every obese American.— Robert F. Kennedy Jr., Trump's HHS nominee
The Hearth Conversation Another angle on the story
Why does the timing of this proposal matter so much? It seems like it's being announced right before a change in power.
Exactly. The rule won't be finalized until January, after Trump takes office. That's the window where it becomes vulnerable. If Kennedy is confirmed as HHS secretary, he could essentially kill it or rewrite it.
And Kennedy opposes these drugs?
Strongly. He's argued the money would be better spent on food subsidies and gym memberships. He sees the drugs as a pharmaceutical industry solution to what he views as a food and lifestyle problem.
But the drugs actually work, right? People lose significant weight.
Yes—15 to 25 percent of body weight. That's real. The issue is cost. Right now they're $1,000 to $1,300 a month. Without insurance, they're only accessible to wealthy people and celebrities.
So the administration is saying Medicare and Medicaid should cover them?
That's the proposal. It would open access to millions of people who can't afford them otherwise. But it costs money—potentially $35 billion over ten years.
And that's the real problem for the incoming administration?
It's the central problem. Trump's team is focused on cutting spending. A $35 billion commitment to weight-loss drugs, even if it saves money long-term by preventing other diseases, is a hard sell politically.
So what happens now?
We wait until January. Kennedy gets confirmed or doesn't. The rule either becomes law or gets blocked. Right now it's in limbo.